Search

Your search keyword '"Engel U"' showing total 484 results
Start Over Author "Engel U"
484 results on '"Engel U"'

116. Myocardial perfusion at fatal infarction:location and size of scintigraphic defects

Author

Hvid-Jacobsen, K, Møller, J T, Kjøller, E, Nielsen, S L, Engel, U, Duus, S, Kanstrup, I L, Jensen, P F, Carlsen, J, Nielsen, Finn Erland, and Skagen, K.

Subjects
Male, Technetium Tc 99m Sestamibi, Coronary Circulation, Myocardium, Journal Article, Humans, Coronary Disease, Female, Heart, Organotechnetium Compounds, Prospective Studies, Aged
Abstract

In a consecutive study of myocardial scintigraphy in acute ischemic syndrome, four patients had 99mTc-hexamibi injected intravenously before they developed fatal cardiogenic shock. Planar scintigraphy was performed after death. Slices of the hearts after autopsy were analyzed for scintigraphic and pathoanatomic abnormalities. Location of perfusion defects in planar views of the heart was in good agreement with the scintigraphied, sliced sections. The extent of infarction judged from inspection and formasan staining was much smaller (7%-40% and 6%-43% of the total slice area) than found at scintigraphy, where 83%-92% of the myocardium showed ischemia as defined by a 99mTc-hexamibi uptake below an arbitrary limit on half maximum uptake. Myocardial hypoperfusion might thus aggravate the functional impairment at myocardial infarction and lead to cardiogenic shock.

Published
1992

133. DNA analysis of Huntington’s disease

Author

Laccone, F., primary, Engel, U., additional, Holinski–Feder, E., additional, Weigell–Weber, M., additional, Marczinek, K., additional, Nolte, D., additional, Morris–Rosendahl, D.J., additional, Zühlke, C., additional, Fuchs, K., additional, Weirich–Schwaiger, H., additional, Schlüter, G., additional, von Beust, G., additional, Vieira–Saecker, A.M. M., additional, Weber, B.H. F., additional, and Riess, O., additional

Published
1999
Full Text
View/download PDF

150. Validation of three BRCA1/ 2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.

Author

Schneegans, S., Rosenberger, A., Engel, U., Sander, M., Emons, G., and Shoukier, M.

Abstract

Many studies have evaluated the performance of risk assessment models for BRCA1/2 mutation carrier probabilities in different populations, but to our knowledge very few studies have been conducted in the German population so far. In the recent study, we validated the performance of three risk calculation models by names BRCAPRO, Myriad and BOADICEA in 183 German families who had undergone molecular testing of mutations in BRCA1 and BRCA2 with an indication based on clinical criteria regarding their family history of cancer. The sensitivity and specificity at the conventional threshold of 10% as well as for a threshold of 20% were evaluated. The ability to discriminate between carriers and non-carriers was judged by the area under the receiver operating characteristics curve. We further focused on the performance characteristic of these models in patients carrying large genomic rearrangements as a subtype of mutations which is currently gaining increasing importance. BRCAPRO and BOADICEA performed almost equally well in our patient population, but we found a lack of agreement to Myriad. The results obtained from this study were consistent with previously published results from other population and racial/ethnic groups. We suggest using model specific decision thresholds instead of the recommended universal value of 10%. We further suggest integrating the CaGene5 software package, which includes BRCAPRO and Myriad, in the genetic counselling of German families with suspected inherited breast and ovarian cancer because of the good performance of BRCAPRO and the substantial ease of use of this software. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results